NeRRe Therapeutics

Executive Summary

NeRRe Therapeutics was a UK-based biopharmaceutical company founded in 2012 that focused on developing small molecule antagonists targeting neurokinin receptors (NK1 and NK2) for chronic cough and other neuronal hypersensitivity disorders. The company aimed to address a significant unmet need in respiratory medicine, as chronic cough affects millions worldwide with limited treatment options. Despite promising preclinical data and a clear mechanistic rationale, NeRRe Therapeutics faced challenges typical of early-stage biotech, including funding uncertainties and the high risk of drug development. The company ceased trading in 2023, and its assets and operations were wound down. As of 2026, no active clinical programs or partnerships remain, and the company is no longer operational.